Clinical protocol: Phase I study of an adenovirus/prostate-specific antigen vaccine in men with metastatic prostate cancer

Human Gene Therapy

Volumn 17, Issue 2, 2006, Pages 220-229

  Lubaroff, David M ^a   Konety, Badrinath ^a   Link, Brian K ^a   Ratliff, Timothy L ^a   Madsen, Tammy ^a   Shannon, Mary ^a   Ecklund, Dixie ^a   Williams, Richard D ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS PROSTATE SPECIFIC ANTIGEN VACCINE; ADENOVIRUS VECTOR; CANCER VACCINE; GELFOAM; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN SPECIFICITY; AQUEOUS SOLUTION; ARTICLE; CANCER PATIENT; CLINICAL PROTOCOL; CLINICAL TRIAL; HUMAN; IMMUNE RESPONSE; MALE; METASTASIS; PHASE 1 CLINICAL TRIAL; PROSTATE CANCER; UNSPECIFIED SIDE EFFECT; VACCINATION;

ADENOVIRIDAE; CANCER VACCINES; CLINICAL PROTOCOLS; CLINICAL TRIALS, PHASE I; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; GELATIN SPONGE, ABSORBABLE; GENETIC VECTORS; HUMANS; MALE; PATIENT SELECTION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

ADENOVIRIDAE;

EID: 32944477518     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2006.17.220     Document Type: Article

References (68)

1. AKLI, S., CAILLAUD, C., VIGNE, E., STRATFORD-PERRICAUDET, L.D., POENARU, L., PERRICAUDET, M., KAHN, A., and PESCHANSKI, M.R. (1993). Transfer of a foreign gene into the brain using adenovirus vectors, Nat. Genet. 3, 224-234.
2. BABIUK, L.A., and TIKOO, S.K. (2000). Adenoviruses as vectors for delivering vaccines to mucosal surfaces. J. Biotechnol. 83, 105-113.
3. BISCHOFF, W., and GOERTTLER, U. (1977). [Successful intra-arterial embolization of bleeding carcinoma of the prostate]. Urologe A. 16, 99-102.
4. BRONTE, V. (2001). Genetic vaccination for the active immunotherapy of cancer. Curr. Gene Ther. 1, 53-100.
5. BURCH, P.A., CROGHAN G.A., GASTINEAU, D.A., JONES, L.A., KAUR, J.S., KYLSTRA, J.W., RICHARDSON, R.L., VALONE, F.H., and VUK-PAVLOVIC, S. (2004). Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: A phase 2 trial. Prostate 60, 197-204.
6. CAVACINI, L.M., DUVAL, M., EDER, J.P., and POSNER, M.R. (2002). Evidence of determinant spreading in the antibody responses to prostate cell surface antigens in patients immunized with prostate-specific antigen. Clin. Cancer Res. 8, 368-373.
7. CHIOCCA, E.A., and SMITH, E.R. (2000). Oncolytic viruses as novel anticancer agents: Turning one scourge against another. Expert Opin. Investig. Drugs 9, 311-327.
8. CONNOLLY, J.B. (2003). Conditionally replicative viruses in cancer therapy. Gene Ther. 10, 712-715.
9. CONRY, R.M., KHAZAELI, M.B., SALEH, M.N., ALLEN, K.O., BARLOW, D.L., MOORE, S.E., CRAIG, D., ARANI, R.B., SCHLOM, J., and LO BUGLIO, A.F. (1999). Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: Comparison of intradermal versus subcutaneous administration. Clin. Cancer Res. 5, 2330-2337.
10. CORDIER, L., DUFFOUR, M.T., SABOURIN, J.C., LEE, M.G., CABBANNES, J., ROGOT, T., PERRICAUDET, M., and HADDADA, H. (1995). Complete recovery of mice from pre-established tumor by direct intra-tumoral delivery of an adenovirus vector harboring the murine IL-2 gene. Gene Ther. 2, 16-21.
11. CORRELL, J.T., PRENTICE, H.R., and WISE, E.C. (1945). Biologic investigations of a new absorbable sponge. Surg. Gynecol. Obstet. 181, 585-589.
12. COUNCIL ON PHARMACY AND CHEMISTRY. (1947). Absorbable gelatin sponge: New and nonofficial remedies. JAMA 135, 921.
13. DARSON, M.F., PACELLI, A., ROCHE, P., RITTENHOUSE, H.G., WOLFERT, R.L., SAEID, M.S., YOUNG, C.Y., KLEE, G.G., TINDALL, D.J., and BOSTWICK, D.G. (1999). Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. Urology 53, 939-944.
14. DAVIDSON, B.L., DORAN, S.E., SHEWACH, D.S., LATTA, J.M., HARTMAN, J.W., and ROESSLER, B.J. (1994). Expression of Escherichia coli β-galactosidase and rat HPRT in the CNS of Macaca mulatta following adenoviral mediated gene transfer. Exp. Neurol. 125, 258-267.
15. EDER, J.P., KANTOFF, P.W., ROPER, K., XU, G., BUBLEY, G.J., BOYDEN, J., GRITZ, L., MAZZARA, G. OH, W.K., ARLEN, P., TSANG, K.Y., PANICALI, D., SCHLOM, J., and KUFE, D.W. (2000). A phase I trial of recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin. Cancer Res. 6, 1632-1638.
16. ELZEY, B.D., RATLIFF, T.L., and LUBAROFF, D.M. (2001). Immunization with type 5 adenovirus recombinant for PSA in combination with ALVAC cytokine gene delivery induces destruction of established prostate tumors. Int. J. Cancer 94, 842-849.
17. FINLAY, J.A., EVANS, C.L., DAY, J.R., PAYNE, J.K., MIKOLAJCZYK, S.D., MILLAR, L.S., KUUS-REICHEL, K., WOLFERT, R.L., and RITTENHOUSE, H.G. (1998). Development of monoclonal antibodies specific for human glandular kallikrein (hK2): Development of a dual antibody immunoassay for hK2 with negligible prostate specific antigen cross-reactivity. Urology 51, 804-809.
18. GALLO, P., DHARMAPURI, S., NUZZO, M., MALDINI, D., IEZZI, M., CAVALLO, F., MUSIANI, P., FORNI, G., and MONACI, P. (2005). Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector. Int. J. Cancer 113, 67-77.
19. GOODMAN, L.S., and GILMAN, A. (1980). Surface-acting drugs. In The Pharmacologic Basis of Therapeutics (Macmillan, New York) p. 955.
20. GRAHAM, F.L., SMILEY, J., RUSSELL, W.C., and NAIRN, R. (1977). Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36, 59-74.
21. GULLEY, J., CHEN, A.P., DAHUT, W., ARLEN, P.M., BASTIAN, A., STEINBERG, S.M., TSANG, K., PANICALI, D., POOLE, D., SCHLOM, J., and HAMILTON, J.M. (2002). Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate 53, 109-117.
22. GULLEY, J.L., ARLEN, P.M., BASTIAN, A., MORIN, S., MARTE, J., BEETHAM, P., TSANG, K.-Y., YOKOKAWA, J., HODGE, J.W., MÉNARD, C., CAMPHAUSEN, K., COLEMAN, C.N., SULLIVAN, F., STEINBERG, S.M., SCHLOM, J., and DAHUT, W. (2005). Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin. Cancer Res. 11, 3353-3362.
23. GURAINICK, W., and BERG, L. (1948). Gelfoam in oral surgery. Oral Surg. 1, 629-632.
24. HANISCH, M.E., BAUM, N., BEACH, P.D., GRIFFITH, D.P., and TYLER, M. (1975). A comparative evaluation of Avitene and Gelfoam for hemostasis in experimental canine prostatic wounds. Invest. Urol. 12, 333-336.
25. HEISER, A., COLEMAN, D., DANNULL J., YANCY, D., MAURICE, M.A., LALLAS, C.D., DAHM, P., NIEDZWIECKI, D. GILBOA, E., and VIEWEG, J. (2002). Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J. Clin. Invest. 109, 409-417.
26. HORWITZ, M.S. Adenoviridae and their replication. (1990). In Virology. B.N. Fields and D.M. Knipe, eds. (Raven Press, New York) pp. 1679-1721.
27. JAFFE, H.A., DANEL, C., LONGENECKER, G., METZGER, M., SETOGUCHI, Y., ROSENFELD, M.A., GANT, T.W., THORGEIRSSON, S.S., STRATFORD-PERRICAUDET, D., PERRICAUDET, M., PAVIRANI, A., LECOCQ, J.-P., and CRYSTAL, R.G. (1992). Adenovirus-mediated in vivo gene transfer and expression in normal rat liver. Nat. Genet. 1, 372-378.
28. JEMAL, A., WARD, E., SAMUELS, A., TIWARI, R.C., GHAFOOR, A., GEUER, E.J., and THUN, M.J. (2005). Cancer statistics, 2005. CA Cancer J. Clin. 55, 10-30.
29. Erratum in: CA Cancer J. Clin. 55, 259.
30. JENKINS, H.P., SENZ, E.H., OWEN, H.W., and JAMPOLIS, R.W. (1946a). Present status of gelatin sponge for control of hemorrhage. JAMA 132, 614-619.
31. JENKINS, H.P., JANDA, R., and CLARKE, J. (1946b). Clinical and experimental observations on the use of gelatin sponge or foam. Surgery 20, 124-132.
32. KAUFMAN, H.L., WANG, W., MANOLA, J., DI PAOLA, R.S., KO, Y.-J., SWEENEY, C., WHITESIDE, T.L., SCHLOM, J., WILDING, G., and WEINER, L.M. (2004). Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): A trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 22, 2122-2132.
33. KOOTSTRA, N.A., and VERMA, I.M. (2003). Gene therapy with viral vectors. Annu. Rev. Pharmacol. Toxicol. 43, 413-439.
34. LEE, Y.C., SIMAMORA, P., and YALKOWSKY, S.H. (1997). Systemic delivery of insulin via an enhancer-free ocular device. J. Pharm. Sci. 86, 1361-1364.
35. LE GAL LA SALLE, G., ROBERT, J.J., BERRARD, S., RIDOUX, V., STRATFORD-PERRICAUDET, L.D., PERRICAUDET, M., and MALLET, J. (1993). An adenovirus vector for gene transfer into neurones and glial cells in the brain. Science 259, 988-990.
36. LI, W., BERENCSI, K., BASAK, S., SOMASUNDARAM, R., RICCIARDI, R.P., GONCZOL, E., ZALOUDIK, J., LINNENBACH, A., MARUYAMA, H., MINIOU, P., and HERLYN, D. (1997). Human colorectal cancer (CRC) antigen CO17-1A/GA/733 encoded by adenovirus inhibits growth of established CRC cell lines. J. Immunol. 159, 763-769.
37. LIU, D.W., TSAO, Y.P., HSIEH, C.H., HSIEH, J.T., KUNG, J.T., CHIANG, C.L., HUANG, S.J., and CHEN, S.L. (2000). Induction of CD8 T cells by vaccination with a recombinant adenovirus expressing human papillomavirus type 16 E5 gene reduces tumor growth. J. Virol. 74, 9083-9089.
38. LUNDWALL, A. (1989). Characterization of the gene for prostate-specific antigen, a human glandular kallikrein. Biochem. Biophys. Res. Commun. 161, 1151-1159.
39. MACDONALD, S.A., and MATHEWS, W.H. (1946). Fibrin foam and Gelfoam in experimental kidney wounds. Annual American Urological Association, July 1946.
40. MEIDENBAUER, N., HARRIS, D.T., SPITLER, L.E., and WHITESIDE, T.L. (2000). Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer. Prostate 43, 88-100.
41. MURPHY, G.P., TJOA, B.A., SIMMONS, S.J., JARISCH, J., BOWES, V.A., RAGDE, H., ROGERS, M., ELGAMAL, A., KENNY, G.M., COBB, O.E., IRETON, R.C., TROYCHAK, M.J., SALGALLER, M.L., and BOYNTON, A.L. (1999). Infusion of dendritic cells pulsed with HLA-A2 specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine involving patients with hormone-refractory metastatic disease. Prostate 38, 73-78.
42. + HRPC patients. Prostate 63, 1-12.
43. PANDHA, H.S., JOHN, R.J., HUTCHINSON, J., JAMES, N. WHELAN, M., CORBISHLEY, C., and DALGLEISH, A.C. (2004). Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumor lysate-pulsed cells: a phase I/II study. BJU Int. 94, 412-418.
44. + Th1 cells and antibodies in HER-w adenovirus vaccine protection against autochthonous mammary carcinomas. J. Immunol. 174, 4228-4236.
45. PARK, M.S., and KIM, Y.B. (1997). Sustained release of antibiotic from a fibrin-gelatin antibiotic mixture. Laryngoscope 107, 1378-1381.
46. PAVLENKO, M., ROOS, A.-K., LUNDQVIST, A., PALMBORG, A., MILLER, A.M., OZENCI, V., BERGMAN, B., EGEVAD, L., HELLSTROM, M., KIESSLING, R., MASUCCI, G., WERSÄLL, P., NILSSON, S., and PISA, P. (2004). A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br. J. Cancer 91, 688-394.
47. PERRICONE, M.A., SMITH, K.A., CLAUSSEN, K.A., PLOG, M.S., HEMPEL, D.M., ROBERTS, B.L., ST GEORGE, J.A., and KAPLAN, J.M. (2004). Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes. J. Immunother. 27, 273-281.
48. RINI, B.I. (2002). Technology evaluation: APC-8015, Dendreon. Curr. Opin. Mol. Ther. 4, 76-79.
49. RITTENHOUSE, H.G., FINLAY, J.A., MIKOLAJCZYK, S.D., and PARTIN, A.W. (1998). Human kallikrein 2 (hK2) and prostate specific antigen (PSA): Two closely related, but distinct, kallikreins in the prostate. Crit. Rev. Clin. Lab. Sci. 35, 275-368.
50. ROSENBERG, S.A., ZHAI, Y., YANG, J.C., SCHWARTZENTRUBER, D.J., HWU, P., MARINCOLA, F.M., TOPALIAN, S.L., RESTIFO, N.P., SEIPP, C.A., EINHORN, J.H., ROBERTS, B., and WHITE, D.E. (1998). Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J. Natl. Cancer Inst. 90, 1894-900.
51. ROSENFELD, M.A., YOSHIMURA, K., TRAPNELL, B.C., YONEYAMA, K., ROSENTHAL, E.R., DALEMANS, W., FUKAYAMA, M., BARGON, J., STIER, L.E., STRATFORD- PERRICAUDET, L., PERRICAUDET, M., GUGGINO, W.B., PAVIRANI, A., LECOCQ, J.-P., and CRYSTAL, R.G. (1992). In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 68, 143-155.
52. RUBIN, S.A., and RORKE, L.B. (1988). Adenovirus vaccines. In Vaccines. S.A. Plotkin and E.A. Mortimer, Jr., eds. (Saunders, Philadelphia, PA) pp. 492-512.
53. SAEDI, M.S., KUUS-REICHEL, K., KUMAR, A., PAYNE, J., MIKOLAJCZYK, S.D., WOLFERT, R.L., and RITTENHOUSE, H.G. (1998). The precursor form of the human kallekrein 2, a kallikrein homologous to prostate specific antigen, is present in human sera and is increased in prostate cancer and benign prostatic hyperplasia. Clin. Chem. 44, 2115-2119.
54. SANDA, M.G., SMITH, D.C., CHARLES, L.G., HWANG, C., PIENTA, K.J., SCHLOM, J., MILENIC, D., PANICALI, D., and MONTIE, J.E. (1999). Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology 53, 260-266.
55. SIEMENS, D.R., ELZEY, B.D., LUBAROFF, D.M., and RATLIFF, T.L. (2001). Restoration of the ability to generate CTL in mice immune to adenovirus by delivery of virus in a collagen-based matrix. J. Immunol. 166, 731-735.
56. SLOVIN, S.F., RAGUPATHI, G., ADLURI, S., UNGERS, G., TERRY, K., KIM, S., SPASSOVA, M., BORNMANN, W.G., FAZZARI, M., DANTIS, L., OLKIEWICZ, K., LLOYD, K.O., LIVINGSTON, P.O., DANISHEFSKY, S.J., and SCHER, H.I. (1999). Carbohydrate vaccines in cancer: Immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. Proc. Natl. Acad. Sci. U.S.A. 96, 5710-5715.
57. SLOVIN, S.F., RAGUPATHI, G., MUSSELLI, C., OLKIEWICZ, K., VERBEL, D., KUDUK, S.D., SCHWARZ, J.B., SAMES, D., DANISHEFSKY, S., LIVINGSTON, P.O., and SCHER, H.I. (2003). Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: Clinical trial results with α-N- acetylgalactosamtne-O-serine/threonine conjugate vaccine. J. Clin. Oncol. 21, 4292-4298.
58. SLOVIN, S.F., RAGUPATHI, G., MUSSELLI, C., FERNANDEZ, C., DIANI, M., VERBEL, D., DANISHEFSKY, S., LIVINGSTON, P., and SCHER, H.I. (2005). Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: Clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer. Cancer Immunol. Immunother. 54, 694-702.
59. SMALL, E.J., FRATESI, P., REESE, D.M., STRANG, G., LAUS, R., PESHWA, M.V., and VALONE, F.H. (2000). Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J. Clin. Oncol. 18, 3894-3903.
60. STEPNICK, D.W., PETERSON, M.K. BODGAN, C., DAVIS, J., WASMAN, J., and MAILER, K. (1995). Effects of tumor necrosis factor α and vascular permeability factor on neovascularization of the rabbit ear flap. Arch. Otolaryngol. Head Neck Surg. 121, 667-672.
61. + T cell responses in patients with metastatic prostate cancer. J. Immunol. 174, 3798-3807.
62. TJOA, B.A., ERICKSON, S.J., BOWES, V.A., RAGDE, H., KENNY, G.M., COBB, O.E., IRETON, R.C., TROYCHAK, J.J., BOYNTON, A.L., and MURPHY, G.P. (1997). Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides. Prostate 32, 272-278.
63. TJOA, B.A., SIMMONS, S.J., BOWES, V.A., RAGDE, H., ROGERS, M., ELGAMAL, A., KENNY, G.M., COBB, O.E., IRETON, R.C., TROYCHAK, M.J., SALGALLER, M.L., BOYNTON, A.L., and MURPHY, G.P. (1998). Evlauation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 36, 39-44.
64. TRIPATHY, S.K., BLACK, H.B., GOLDWASSER, E., and LEIDEN, J.M. (1996). Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat. Med. 2, 545-550.
65. TSAO, H., MILLMAN, P., LINETTE, G.P., HODI, P.S., SOBER, A.J., GOLDBERG, M.A., and HALUSKA, F.G. (2002). Hypopigmentation associated with an adenovirus-mediated gp100/MART-1-transduced dendritic cell vaccine for metastatic melanoma. Arch. Dermatol. 138, 799-802.
66. + T lymphocytes. Clin. Cancer Res. 10, 828-839.
67. YANG, Y., LI, Q., and ERTL, H.C. (1995). Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol. 69, 2004-2015.
68. ZHANG, W.W. (1999). Development and application of adenoviral vectors for gene therapy of cancer. Cancer Gene Ther. 6, 113-138.